%0 Journal Article
%T 白蛋白结合型紫杉醇在胃癌治疗中的最新临床研究进展<br>Recent Research Progress of Albumin-Bound Paclitaxel in the Treatment of Gastric Cancer
%A 翁湧
%J Advances in Clinical Medicine
%P 6129-6132
%@ 2161-8720
%D 2021
%I Hans Publishing
%R 10.12677/ACM.2021.1112909
%X 胃癌是最常见的恶性肿瘤之一，我国是胃癌的高发区域，化疗是治疗胃癌的主要方法之一。在胃癌化疗药物中主要的药物包含紫杉醇类、铂类、氟化嘧啶类等。白蛋白结合型紫杉醇(NAB-P)为紫杉醇的特殊靶向制剂，近年来在胃癌治疗方面的临床应用逐渐增多，大量研究表明其疗效性及安全性较好。本文就白蛋白结合型紫杉醇在胃癌治疗中最新研究进展作一综述。<br />
Gastric cancer is one of the most common malignant tumors. My country is a high-incidence area for gastric cancer. Chemotherapy is one of the main methods to treat gastric cancer. The main drugs used in gastric cancer chemotherapy drugs include paclitaxel, platinum, and fluorinated pyrimidines. Albumin-bound paclitaxel (NAB-P) is a special targeted preparation of paclitaxel. In recent years, its clinical application in the treatment of gastric cancer has gradually increased. A large number of studies have shown that its efficacy and safety are better. This article reviews the latest research progress of albumin-bound paclitaxel in the treatment of gastric cancer.
%K 胃癌，白蛋白结合型紫杉醇，化疗，研究进展<br>Gastric Cancer
%K Albumin-Bound Paclitaxel
%K Chemotherapy
%K Research Progress
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=47638